LINCOLN vs NEULANDLAB: Stock Comparison
NEULAND LAB is the larger company by market capitalisation. LINCOLN PHARMA shows a lower P/E, a higher dividend yield and lower leverage, while NEULAND LAB shows a higher ROE, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LINCOLN leads 4; NEULANDLAB leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LINCOLN | NEULANDLAB |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | LINCOLN | NEULANDLAB |
|---|---|---|
| Live Price | ₹620.8 | ₹22,660 |
| Day Change | -0.3% | -1% |
| Volume | 29,091 | 21,110 |
| 52-Week High | ₹770 | ₹23,881 |
| 52-Week Low | ₹440 | ₹11,500 |
| Distance from 52W High | -19.38% | -5.11% |
Valuation
| Metric | LINCOLN | NEULANDLAB |
|---|---|---|
| Market Cap | ₹1,240 Cr | ₹29,101 Cr |
| P/E Ratio | 12.83x | 59.08x |
| P/B Ratio | 1.63x | 15.69x |
| EPS | ₹18.09 | ₹115.1 |
| Book Value | ₹378.25 | ₹1,461.02 |
| Dividend Yield | 0.3% | 0.15% |
Growth
| Metric | LINCOLN | NEULANDLAB |
|---|---|---|
| Revenue Growth (TTM YoY) | 11.4% | 136.4% |
| EPS Growth (TTM YoY) | 0.6% | 664.4% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0.21% |
Profitability & Leverage
| Metric | LINCOLN | NEULANDLAB |
|---|---|---|
| ROE | 11.6% | 19.46% |
| ROCE | 11.97% | 19.06% |
| Net Margin | 13.1% | 17.99% |
| Operating Margin | 17.38% | 25.29% |
| Debt to Equity | 0.01x | 0.11x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | LINCOLN | NEULANDLAB |
|---|---|---|
| Promoter Holding | 49.78% | 32.62%▼ 0.01 pp |
| FII Holding | 4.6%▼ 0.59 pp | 21.08%▲ 0.62 pp |
| DII Holding | 0.27%▼ 0.82 pp | 16.51%▲ 0.67 pp |
| Public Holding | 45.36%▲ 1.42 pp | 29.79%▼ 1.28 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LINCOLN PHARMA and NEULAND LAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.